Pharma Stock Performance 2025
Stock performance across the pharmaceutical sector varied widely in 2025. While some companies delivered strong shareholder returns as strategies gained traction, others faced headwinds from operational challenges, valuation resets, or macroeconomic pressures.
Here is an overview of the annual performance of several leading biopharma companies (market capitalization > $10B). Only stocks with gains above 5% or declines below −5% are shown. The following are some of the top performers of 2025:
↑ Insmed Incorporated
↑ Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
↑ Bayer
↑ BeOne Medicines
↑ Genmab
↑ Teva Pharmaceuticals
↑ Johnson & Johnson
↑ Novartis
↑ AstraZeneca
↑ Eli Lilly and Company
↑ Gilead Sciences
↑ GSK
↑ argenx
↑ AbbVie
↑ Amgen
↑ Roche
